In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors
- MSKCC
- Research Organization:
- Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- National Institutes of Health (NIH)
- OSTI ID:
- 1087759
- Journal Information:
- PLoS One, Vol. 8, Issue (5) ; 05, 2013
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
SU-C-210-01: Are Clinically Relevant Dosimetric Endpoints Significantly Better with Gating of Lung SBRT Vs. ITV-Based Treatment?: Results of a Large Cohort Investigation Analyzing Predictive Dosimetric Indicators as a Function of Tumor Volume and Motion Amplitude
Serum half-life and tumor localization of a chimeric antibody deleted of the C sub H 2 domain and directed against the disialoganglioside GD2
Tumor sensitizing effect by misonidazole in a clinically relevant radiation dose range
Journal Article
·
Mon Jun 15 00:00:00 EDT 2015
· Medical Physics
·
OSTI ID:1087759
+2 more
Serum half-life and tumor localization of a chimeric antibody deleted of the C sub H 2 domain and directed against the disialoganglioside GD2
Journal Article
·
Wed Aug 01 00:00:00 EDT 1990
· Proceedings of the National Academy of Sciences of the United States of America; (USA)
·
OSTI ID:1087759
Tumor sensitizing effect by misonidazole in a clinically relevant radiation dose range
Journal Article
·
Thu Mar 01 00:00:00 EST 1984
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:1087759